The BioPharm Brief: New Glioblastoma Combo Immunotherapy Advances Adaptive Neuro-Oncology Trials

Welcome to The BioPharm Brief, your daily snapshot of key developments in biopharmaceutical research and clinical innovation. Today we’re looking at a new collaborative immunotherapy approach for one of the most challenging solid tumors, glioblastoma multiforme, and what it could mean for future neuro‑oncology strategies.

INOVIO and Akeso have announced a clinical collaboration to evaluate a novel combination immunotherapy regimen for glioblastoma that involves integrating targeted DNA‑encoded tumor antigen priming with dual immune checkpoint inhibition. The partnership will investigate INO‑5412 (composed of INOVIO’s DNA immunotherapy candidates INO‑5401 and INO‑9012) in combination with Akeso’s bispecific antibody, cadonilimab, which targets both PD‑1 and CTLA‑4 pathways. This combination will be studied within the Phase II adaptive INSIGhT trial sponsored by Dana‑Farber Cancer Institute. Initial dosing is expected in the second half of 2026.

Glioblastoma remains a highly aggressive and often treatment‑refractory brain cancer, where median survival under current standard‑of‑care regimens has historically shown only modest improvement. The collaborative strategy aims to prime tumor‑specific immune responses while countering multiple immunosuppressive mechanisms within the tumor microenvironment. This approach has the potential to overcome the limitations seen with checkpoint inhibition alone. Previous exploratory studies combining INO‑5401 and immune checkpoint inhibitors have suggested meaningful immune activation, which has motivated the addition of dual checkpoint blockade in this next phase of investigation.

The use of an adaptive platform trial design like INSIGhT highlights a broader trend toward more efficient screening of experimental therapies in difficult‑to‑treat cancers by enabling multiple investigational arms to be assessed against a shared control. As immuno‑oncology continues to evolve, coordinated combination approaches that integrate antigen priming with enhanced checkpoint modulation may offer new avenues for addressing historically unmet needs in neuro‑oncology.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of key developments:

• INOVIO and Akeso are collaborating on a combination immunotherapy regimen targeting glioblastoma’s complex immune resistance.
• The INSIGhT adaptive trial will evaluate INO‑5412 plus cadonilimab beginning in late 2026.
• Integrated strategies pairing immune priming with dual checkpoint blockade represent an emerging direction in solid tumor immunotherapy.